Skip to main content

Table 5 Concentration, coordination and authority of the consensus content

From: Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression

Consensus

Mean

Standard deviation

Full score ratio

Coefficient of variation

Coordination coefficient

Judgment coefficient

Familiarity coefficient

Authority coefficient

Immune monitoring

    

0.28*

   

Patients with sepsis had immunosuppression

    

0.05

0.94 ± 0.10

0.72 ± 0.35

0.83 ± 0.20

 Presence of innate immunosuppression

7.95

1.56

55

0.20

    

 Presence of acquired immunosuppression

8.23

1.23

59

0.15

    

Sepsis-related immune function monitoring

    

0.09

0.95 ± 0.08

0.73 ± 0.35

0.84 ± 0.19

 Initiated immune monitoring within 48 h after diagnosis of sepsis

7.95

1.40

50

0.18

    

 Need for dynamic monitoring of immune status

8.27

1.52

68

0.18

    

Patients with sepsis had high risk factors for immunosuppression

    

0.49*

0.97 ± 0.06

0.76 ± 0.33

0.86 ± 0.18

 Elderly (age ≥ 65 years old)

7.82

0.91

27

0.12

    

 Patients with malignant tumors under radiotherapy/chemotherapy within 3 months

8.41

0.73

55

0.09

    

 Patients under long-term immunosuppressive or steroids therapy

8.64

0.66

73

0.08

    

 Malnutrition (BMI < 18.5 kg/m2)

7.14

1.36

18

0.19

    

 Secondary infection

7.23

1.48

18

0.20

    

Monitoring indicators of immunosuppression in patients with sepsis

    

0.24*

0.96 ± 0.07

0.73 ± 0.33

0.84 ± 0.18

 Decreased mHLA-DR

8.18

0.85

41

0.10

    

 Reduced responsiveness of monocytes to endotoxin stimulation

7.68

1.04

23

0.14

    

 Decreased peripheral blood lymphocyte count

8.05

1.05

45

0.13

    

 Increased regulatory T cell ratio

7.41

0.85

9

0.12

    

 Th1/Th2 imbalance

7.45

1.22

27

0.16

    

 Decreased peripheral blood immunoglobulin (IgA, IgM and IgG) concentrations

6.55

1.54

9

0.23

    

Immunotherapy

    

0.32*

   

Immunomodulatory therapy for sepsis

    

0.02

0.92 ± 0.10

0.73 ± 0.31

0.82 ± 0.17

 Percentage of mHLA-DR < 60%

7.05

1.29

9

0.18

    

 mHLA-DR < 15,000 AB/C

7.00

1.02

36

0.15

    

 Total lymphocytes < 1.1 × 109/L

7.00

1.07

5

0.15

    

 Presence of risk factors for immunosuppression

7.05

1.59

27

0.23

    

Immunomodulatory drugs

    

0.33*

0.94 ± 0.08

0.72 ± 0.32

0.83 ± 0.18

 Recombinant interferon γ

5.59

1.50

5

0.27

    

 IgG

5.91

1.90

9

0.32

    

 Recombinant GM-CSF

6.23

1.63

9

0.26

    

 Tα1

7.32

1.84

27

0.25

    

Immunomodulatory therapy required dynamic monitoring of immune function

8.41

0.80

55

0.09

 

0.92 ± 0.09

0.72 ± 0.34

0.82 ± 0.18

Endpoint of immunomodulatory therapy

    

0.01

0.91 ± 0.10

0.69 ± 0.28

0.80 ± 0.15

 mHLA-DR ≥ 15,000 AB/C

6.91

1.44

14

0.21

    

 Percentage of mHLA-DR ≥ 60%

6.73

1.49

14

0.22

    

 Total lymphocytes ≥ 1.1 × 109/L

6.95

1.05

0

0.15

    
  1. *P < 0.05. BMI body mass index, GM-CSF granulocyte–macrophage colony-stimulating factor, Ig immunoglobulin, mHLA-DR monocyte human leukocyte antigen DR, Th helper T cell, Tα1 thymosin α1
Back to article page

Military Medical Research

ISSN: 2054-9369